Gene · 5819
Papers2,573
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
341 to 360 of 2,573
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Cuproptosis related gene PDHB is identified as a biomarker inversely associated with the progression of clear cell renal cell carcinoma. | BMC Cancer | 2023 | 37641032 | PubTator, text mining | PubMed |
| Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy. | Front Immunol | 2023 | 37638058 | PubTator, text mining | PubMed |
| Antibody-Drug Conjugates: Ushering in a New Era of Cancer Therapy. | Pharmaceutics | 2023 | 37631232 | PubTator, text mining | PubMed |
| Oncolytic Viruses and Immune Checkpoint Inhibitors: The "Hot" New Power Couple. | Cancers (Basel) | 2023 | 37627206 | PubTator, text mining | PubMed |
| Natural Killer Cell Activation by Ubiquitin-specific Protease 6 Mediates Tumor Suppression in Ewing Sarcoma. | Cancer Res Commun | 2023 | 37615015 | PubTator, text mining | PubMed |
| Single cell transcriptomic analyses implicate an immunosuppressive tumor microenvironment in pancreatic cancer liver metastasis. | Nat Commun | 2023 | 37612267 | PubTator, text mining | PubMed |
| TIGIT can inhibit T cell activation via ligation-induced nanoclusters, independent of CD226 co-stimulation. | Nat Commun | 2023 | 37596248 | PubTator, text mining | PubMed |
| The Progress of Platelets in Breast Cancer. | Cancer Manag Res | 2023 | 37589033 | PubTator, text mining | PubMed |
| IRX2 regulates angiotensin II-induced cardiac fibrosis by transcriptionally activating EGR1 in male mice. | Nat Commun | 2023 | 37587150 | PubTator, text mining | PubMed |
| CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer. | BMC Gastroenterol | 2023 | 37582713 | PubTator, text mining | PubMed |
| Combined Use of Immune Checkpoint Inhibitors and Phytochemicals as a Novel Therapeutic Strategy against Cancer. | J Cancer | 2023 | 37576404 | PubTator, text mining | PubMed |
| Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature. | Int J Mol Sci | 2023 | 37569880 | PubTator, text mining | PubMed |
| Clinical Significance of Nectins in HCC and Other Solid Malignant Tumors: Implications for Prognosis and New Treatment Opportunities-A Systematic Review. | Cancers (Basel) | 2023 | 37568798 | PubTator, text mining | PubMed |
| ADAM17 targeting by human cytomegalovirus remodels the cell surface proteome to simultaneously regulate multiple immune pathways. | Proc Natl Acad Sci U S A | 2023 | 37561786 | PubTator, text mining | PubMed |
| Memory-like Differentiation, Tumor-Targeting mAbs, and Chimeric Antigen Receptors Enhance Natural Killer Cell Responses to Head and Neck Cancer. | Clin Cancer Res | 2023 | 37556118 | PubTator, text mining | PubMed |
| The yes-associated protein (YAP) is associated with resistance to anti-GD2 immunotherapy in neuroblastoma through downregulation of ST8SIA1. | Oncoimmunology | 2023 | 37554309 | PubTator, text mining | PubMed |
| Proteomic analysis of 92 circulating proteins and their effects in cardiometabolic diseases. | Clin Proteomics | 2023 | 37550624 | PubTator, text mining | PubMed |
| The novel role of LDHA/LDHB in the prognostic value and tumor-immune infiltration in clear cell renal cell carcinoma. | PeerJ | 2023 | 37547725 | PubTator, text mining | PubMed |
| Natural killer cell-derived exosomes for cancer immunotherapy: innovative therapeutics art. | Cancer Cell Int | 2023 | 37543612 | PubTator, text mining | PubMed |
| Molecular and structural basis of TIGIT: Nectin-4 interaction, a recently discovered pathway crucial for cancer immunotherapy. | Biochem Biophys Res Commun | 2023 | 37542773 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5819/papers?page=18